

# Myovant and Pfizer Announce Transformative Relugolix Collaboration



December 28, 2020





# Introduction

**Ryan Crowe**

**Vice President, Investor Relations**

Myovant Sciences, Inc.

# Forward-Looking Statements

This presentation contains forward-looking statements, including without limitation, statements related to Myovant Sciences' expectations, including Myovant's aspiration to redefine care for women and for men; the potential benefits of the collaboration with Pfizer, including Myovant Sciences' growth opportunities in relugolix franchise, its commercial potential for ORGOVYX™ and relugolix combination tablet, its financial position, and potential expansion of new medicine pipeline; the timing, payments, anticipated actions and other arrangements under the collaboration agreement; Myovant's expectations regarding the potential benefits and commercial launch of ORGOVYX and the goal to establish ORGOVYX as the new standard of care in advanced prostate cancer; the timing and success of Myovant's future regulatory filings and potential approvals; and Myovant's business strategies, financial condition and trends, potential growth opportunities, and expectations or probabilities for success. Forward-looking statements can be identified by "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "to be," "will," "would," or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identifying words. Myovant cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Myovant Sciences' forward-looking statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, unforeseen circumstances or other disruptions to normal business operations arising from or related to the COVID-19 pandemic; whether Myovant's collaboration with Pfizer will be successful; Myovant's dependence on the success of ORGOVYX and its other product candidates; Myovant's ability to sustain a commercial field organization and distribution network; the degree of acceptance of ORGOVYX among physicians, patients, healthcare payors, patient advocacy groups, and the general medical community; Myovant's ability to obtain favorable coverage and reimbursement from third-party payors for ORGOVYX and its other product candidates; and Myovant's reliance on third parties for the manufacture of ORGOVYX and its other product candidates. Myovant Sciences cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could materially affect Myovant Sciences' operations and future prospects or which could cause actual results to differ materially from expectations include, but are not limited to, the risks and uncertainties listed in Myovant Sciences' filings with the United States Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Myovant Sciences' Quarterly Report on Form 10-Q filed on November 12, 2020, as such risk factors may be amended, supplemented or superseded from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for its management to predict all risk factors, nor can Myovant assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, Myovant undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.



# Overview of Relugolix Collaboration

**Lynn Seely, MD**  
**Chief Executive Officer**  
Myovant Sciences, Inc.

# Transformative Collaboration to Fully Unlock the Potential of Relugolix in Oncology and Women's Health



+



- ✓ Myovant and Pfizer to jointly develop and commercialize ORGOVYX and relugolix combination tablet in the U.S. and Canada
- ✓ Profits and certain expenses related to relugolix development and commercialization to be shared equally
- ✓ Myovant to receive up to \$4.2 billion, including a \$650 million upfront payment, \$200 million of potential regulatory milestones as well as tiered sales milestones
- ✓ Pfizer retains exclusive option to commercialize relugolix in oncology outside the U.S. and Canada<sup>1</sup>

# Relugolix Franchise Strengthened with Pfizer



## ESTABLISHED LEADERSHIP IN PROSTATE CANCER

XTANDI® is a leading prostate cancer therapeutic and is prescribed with ADT

Strong double-digit U.S. growth for XTANDI® in 2020, despite COVID-19 pandemic

## DOUBLES PROSTATE CANCER SALES FORCE

Myovant's uro-oncology sales force of 100

+

Pfizer's uro-oncology sales force of > 100

## RICH HERITAGE IN WOMEN'S HEALTH AND LEADER IN DTC PROMOTION

Strong relationships established with OB/GYNs

Scale and expertise in consumer marketing, media buying, and data analytics and insights


# Myovant and Pfizer to Position ORGOVYX as the New Standard of Care Androgen Deprivation Therapy



## Educate Prescribers

**Educate oncologists and urologists to drive confidence and intent to prescribe**

- Highly experienced sales team
- Engaging “Now Approved” materials



## Establish Broad Access

**Enable seamless prescribing and treatment initiation**

- Broad payer coverage
- Specialty pharmacy distribution
- Comprehensive patient support program



## Engage Patients

**Ensure patients & care partners are aware of ORGOVYX and participate in treatment decisions**

- Targeted awareness campaign to drive patient engagement



# Financial Review

**Frank Karbe**

**President and Chief Financial Officer**

Myovant Sciences, Inc.

# Myovant Eligible to Receive Up to \$4.2 Billion from Pfizer

## 50/50 Profit Split with Significant Milestone Payments

### Total Payments

- Upfront payment: \$650 million
- \$200 million in regulatory milestones split evenly upon each FDA approval for relugolix combination tablet in uterine fibroids and endometriosis
- Tiered sales milestones based on annual net revenues for relugolix in oncology and women's health indications in the U.S. and Canada

### Profit Split in U.S. & Canada

- Myovant to record revenues
- Myovant and Pfizer to equally share profits from the commercialization of relugolix
- Myovant and Pfizer to share certain expenses associated with development and commercialization of relugolix

### International Oncology Option

- Pfizer receives exclusive option to commercialize relugolix in oncology outside the U.S. and Canada<sup>1</sup>
- If the option is exercised:
  - Pfizer will pay Myovant \$50 million
  - Myovant will be eligible to receive a double-digit royalty on net sales

# Accelerating Myovant's Transformation

**Strengthens financial position and potential for significantly increased near, medium, and long-term cash flows**

- ✓ Upfront payment, cash on hand, and remaining committed financing from DSP total approximately \$900 million
- ✓ Expense sharing to reduce cash burn related to relugolix development and commercialization
- ✓ Eligible to receive significant regulatory and sales milestones, starting as soon as 1H 2021

**Allows Myovant to expand and accelerate pipeline by leveraging proven development engine**

- ✓ Advance life-cycle opportunities for relugolix in oncology and women's health with Pfizer
- ✓ Continue development of MVT-602, our novel oligopeptide kisspeptin-1 receptor agonist
- ✓ Provides resources to expand pipeline beyond relugolix and MVT-602



# Myovant Well-Positioned for Commercial Success and Long-Term Growth

## January 2021

Launch ORGOVYX in U.S.

## First-Half 2021

EU regulatory submission for advanced prostate cancer

U.S. regulatory submission for endometriosis

## June 1, 2021

FDA target action date for uterine fibroids

Maximizes commercial potential for ORGOVYX and relugolix combination tablet

Provides strong validation of the differentiated profile for ORGOVYX in advanced prostate cancer and relugolix combination tablet in women's health

Fortifies Myovant's financial position with potential to receive up to \$4.2 billion of total payments, including a \$650 million upfront payment

Allows Myovant to further expand and invest in pipeline of potential medicines

# Q&A Panel

Myovant Sciences, Inc.



**Lynn Seely, MD**  
Chief Executive Officer



**Frank Karbe**  
President and  
Chief Financial Officer



**Adele Gulfo**  
Interim Chief  
Commercial Officer



**Juan Camilo Arjona, MD**  
Chief Medical Officer



*Redefining Care.  
For Women. For Men. For You.*

**[investors@myovant.com](mailto:investors@myovant.com)**